A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma

Inclusion Criteria: * Patients with clinical or histological diagnosis of HCC based on the guidelines of the AJCC * Patients with advanced HCC with unilobar advanaced involvement: right lobe ± S4 segment or left lobe ± S4 segment) * Patients with single large HCC or multinodular HCC * Single \& 5cm \< size \< 15cm * 2-5 nodules \& maximal sized 4-15cm \& sum of diameters ≦ 25cm * Infiltrative type \& unilobular involvement on liver MRI * Segmental or lobar portal vein invasion can be included. * Age : 20 years to 80 years * ECOG Performance Status of 0 to 2 * Child-Pugh class A (Child-Pugh score 5-6), B (CP score 7) * Adequate bone marrow, liver function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening: * WBC count ≧ 1,000/mm3 * Absolute neutrophil count \> 500/mm3 * Hb ≧ 7.0 g/dL * Platelet count \> 100,000 /mm3 * Bilirubin ≦ 3 mg/dL * Adequate clotting function: INR ≦ 2.3 or ≦ 6sec Exclusion Criteria: * Child-Pugh score ≧ 8 * ECOG Performance Status ≧ 3 * Patients with chronic kidney disease or serum creatinine ≥ 1.2 mg/dL * History of organ allograft * Patients with uncontrolled co-morbidity which needs treatment * Patients who have received prior systemic chemotherapy * Patients who have received Capecitabine within 8 weeks * Patients with extrahepatic metastasis * Main portal vein invasion * Patients with lymph node metastasis * Bilobar involvement * Bulk disease(Tumor volume \>70% of the target liver volume, or tumor nodules too numerous to count) * Pregnancy